Clinical Trial Update: Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 neoadjuvant trial evaluating pembrolizumab in combination with gemcitabine for cis-eligible and cis-ineligible urothelial carcinoma (bladd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Jason R. Brown | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-03-18